Processa Pharmaceuticals PCSA 深 沪
等待开盘 09-19 09:30:00 美东时间
0.2074
+0.001
+0.29%
华盛通- 最 高0.2107
- 今 开0.2094
- 成交量 200.70万股
- 最 低 0.196
- 昨 收 0.2068
- 总市值 1044.24万
- 52周最高 1.50
- 市盈率 静 --
- 换手率 3.99%
- 52周最低 0.15
- 委 比 -82.15%
- 总股本 5034.91万
- 历史最高 284.80
- 量 比 0.90
- 振 幅 7.11%
- 历史最低 0.15
- 每 手 1
- 风险率 3.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Processa Pharmaceuticals Reschedules Special Shareholder Meeting
Processa Pharmaceuticals ( ($PCSA) ) has issued an announcement. On September 2...
09-10 22:59
Processa Pharmaceuticals Adjourns Special Shareholder Meeting
Processa Pharmaceuticals ( ($PCSA) ) has shared an announcement. On September 2...
09-03 05:27
HC Wainwright & Co. Maintains Buy on Processa Pharmaceuticals, Lowers Price Target to $1
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharmaceuticals (NASDAQ:PCSA) with a Buy and lowers the price target from $2 to $1.
09-02 19:18
Processa Pharmaceuticals Relocates 2025 Stockholder Meeting
Processa Pharmaceuticals ( ($PCSA) ) has issued an announcement. On August 25, ...
08-26 05:48
Processa Pharma Q2 EPS $(0.25) Misses $(0.20) Estimate
Processa Pharma (NASDAQ:PCSA) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.20) by 25 percent. This is a 75.25 percent increase over losses of $(1.01) per share from
08-08 05:54
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
Processa Pharmaceuticals secured strategic investments and is exploring blockchain-based assets as part of its financial strategy to diversify capital, enhance flexibility, and reduce dilution for shareholders. The company aims to leverage emerging financial technologies for long-term value creation while maintaining regulatory compliance. CEO George Ng highlighted the focus on innovative financial strategies to support shareholders and stakehold...
08-07 12:30
Processa Pharmaceuticals Reschedules Annual Shareholder Meeting
Processa Pharmaceuticals ( ($PCSA) ) has provided an announcement. On June 30, ...
07-16 00:57
Processa Pharmaceuticals Provides Portfolio and Business Update
Processa Pharmaceuticals announced updates on their product pipeline, including a signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852, with potential milestone payments of up to $454 million. The company continues enrolling patients in the Phase 2 study of PCS6422 for metastatic breast cancer, expecting interim data in the second half of 2025. Processa also strengthened its balance sheet with a $7M capit...
07-01 13:00
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
HC Wainwright & Co. Maintains Buy on Processa Pharmaceuticals, Lowers Price Target to $2
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharmaceuticals (NASDAQ:PCSA) with a Buy and lowers the price target from $6 to $2.
06-30 18:57
